STOCK-BASED COMPENSATION | 13 – STOCK-BASED COMPENSATION 2015 Equity Incentive Plan Stock Options The following table summarizes the stock option activity for the three months ended March 31, 2024: Weighted Weighted Number Average Average of Exercise Fair Options Price Value Outstanding as of January 1, 2024 368,190 $ 7.93 $ 2.82 Granted — — — Exercised (65,245) 8.03 3.09 Forfeited — — — Outstanding as of March 31, 2024 302,945 $ 7.91 $ 2.76 Exercisable as of March 31, 2024 302,945 $ 7.91 $ 2.76 The following table summarizes certain information about the options outstanding as of March 31, 2024: Options Outstanding and Unvested, Options Outstanding and Exercisable, March 31, 2024 March 31, 2024 Weighted Weighted Weighted Average Weighted Average Weighted Average Exercise Price of Average Remaining Average Remaining Outstanding Number of Exercise Contractual Number of Exercise Contractual Options Options Price Life Options Price Life $ 7.91 — $ — — 302,945 $ 7.91 2.13 As of March 31, 2024 and December 31, 2023, a total of 302,945 and 368,190 stock options were outstanding, respectively. There was no remaining unamortized stock-based compensation as of March 31, 2024. F or the three months ended March 31, 2024 and 2023, the Company recognized amortization expense of the fair value of its stock options, which is included in General and administrative expenses, as follows: For the Three Months Ended March 31, 2024 2023 General and administrative expenses $ 6 $ 42 Restricted Stock Units The Company has granted restricted stock units (“RSUs”) under the Company’s 2015 Equity Incentive Plan, as amended (the “2015 Plan”), to certain members of the Board of Directors and certain executives and employees of the Company, which represent the right to receive a share of common stock, or in the sole discretion of the Company’s Compensation Committee, the value of a share of common stock on the date that the RSU vests. As of March 31, 2024 and December 31, 2023, 974,823 and 808,880 shares of the Company’s common stock were outstanding in respect of the RSUs, respectively. Such shares will only be issued in respect to vested RSUs issued to directors when the director’s service with the Company as a director terminates. Such shares of common stock will only be issued to executives and employees when their RSUs vest under the terms of their grant agreements and the 2015 Plan. The RSUs that have been issued to certain members of the Board of Directors generally vest on the date of the annual shareholders meeting of the Company following the date of the grant. three The table below summarizes the Company’s unvested RSUs for the three months ended March 31, 2024: Weighted Number of Average Grant RSUs Date Price Outstanding as of January 1, 2024 563,705 $ 16.47 Granted 174,692 18.27 Vested (171,336) 16.34 Forfeited — — Outstanding as of March 31, 2024 567,061 $ 17.06 The total fair value of the RSUs that vested during the three months ended March 31, 2024 and 2023 was $3,410 and $3,369 , respectively. The total fair value is calculated as the number of shares vested during the period multiplied by the fair value on the vesting date. The following table summarizes certain information of the RSUs unvested and vested as of March 31, 2024: Unvested RSUs Vested RSUs March 31, 2024 March 31, 2024 Weighted Weighted Average Weighted Average Remaining Average Number of Grant Date Contractual Number of Grant Date RSUs Price Life RSUs Price 567,061 $ 17.06 1.93 296,175 $ 12.53 The Company is amortizing these grants over the applicable vesting periods, net of anticipated forfeitures. As of March 31, 2024, unrecognized compensation cost of For the three months ended March 31, 2024 and 2023, the Company recognized nonvested stock amortization expense for the RSUs, which is included in General and administrative expenses as follows: For the Three Months Ended March 31, 2024 2023 General and administrative expenses $ 1,154 $ 1,517 Performance-Based Restricted Stock Units The Company has granted performance-based restricted stock units (“PRSUs”) under the 2015 Plan to certain employees of the Company, some of which are contingent upon the Company’s relative total shareholder return (“TSR”) and some of which are contingent upon the Company’s return on invested capital (”ROIC”) for a three-year performance period ending December 31, 2025 and December 31, 2026. The TSR is calculated based on the Company’s total shareholder return compared to that of certain peer companies specified in the award agreements over the performance period and is calculated based on the change in the average daily closing stock price over a 20 trading-day period from the beginning to the end of the performance period, including reinvested dividends. The total quantity of PRSUs eligible to vest under these awards range from zero to 200% of the target based on actual relative TSR performance during the performance period. The grant date fair value of the TSR awards was estimated using a Monte Carlo simulation model. Compensation for these awards, which are subject to market conditions, is being amortized over the service period. The grant date fair value of the ROIC awards was estimated using the closing share price of the Company’s stock on the date of grant. The total quantity of PRSUs eligible to vest under these awards range from zero to 200% of the target based on actual ROIC performance during the performance period. As such ROIC awards are subject to performance conditions and compensation cost is recognized over the service period based on the amount of awards that the Company believes is probable that will vest. To the extent the Company’s estimate changes, the Company will recognize a cumulative catch up in subsequent reporting periods. The table below summarizes the Company’s unvested PRSUs for the three months ended March 31, 2024: Number of PRSUs Outstanding as of January 1, 2024 79,838 Granted 99,065 Vested — Forfeited — Outstanding as of March 31, 2024 178,903 The PRSUs, if earned, will ordinarily vest during the first quarter after the three-year performance period and the recipient will receive a share of common stock for each earned PRSU. If of the target amount of the PRSUs originally granted. However, based on actual performance, the number of PRSUs earned will change based on the ranges described above. As of March 31, 2024, unrecognized compensation cost of Significant inputs used in the estimation of the fair value of these awards outstanding as of March 31, 2024 and December 31, 2023 are as follows: Significant Input March 31, 2024 December 31, 2023 Closing share price of our common stock $14.36 to $18.17 $14.36 to $16.30 Risk-free rate of return 3.81% to 4.38% 3.81% to 4.38% Expected volatility of our common stock 48.34% to 54.53% 53.38% to 54.53% Holding period discount 0% 0% Simulation term (in years) 2.54 to 2.86 2.54 to 2.72 Range of target 0% to 200% 0% to 200% For the three months ended March 31, 2024 and 2023, the Company recognized nonvested stock amortization expense for the PRSUs, which is included in General and administrative expenses as follows: For the Three Months Ended March 31, 2024 2023 General and administrative expenses $ 222 $ — |